Immutep Receives ~A$0.86 Million R&D Tax Incentive
The rebate provides non-dilutive funding for research and development of product candidates efti and IMP761.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immutep (IMMP) received an A$856,669 cash rebate from the Australian Federal Government’s tax incentive program for research and development. The rebate covers eligible activities conducted in fiscal 2025. AusIndustry’s approval of an Advance overseas finding made certain overseas research activities eligible alongside Australian activities.
The company will use the non-dilutive funding to advance research on efti and IMP761 and expects its cash to last into the first half of CY2028. Immutep also receives France’s CIR incentive and received its first German Forschungszulage payment in Q4 FY26. Further German payments remain subject to statutory application, assessment and review, with uncertain amounts and timing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Expected cash reach extends into the first half of CY2028.
- Minor pointA$856,669 cash rebate provides non-dilutive funding for further research on efti and IMP761.
- Minor pointAdvance overseas finding approval extended Australian tax incentive eligibility to certain overseas research activities.
- Minor pointFrench CIR tax incentive supports eligible European Union research expenditure through Immutep S.A.S.
- Minor pointFirst German Forschungszulage payment received in Q4 FY26 for qualifying internal research personnel costs.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Potential further German payments require statutory application, assessment and review; amounts and timing remain uncertain.
Key Figures
- Cash rebate
- A$856,669
- Australian R&D tax incentive for eligible 2025 fiscal-year expenditure
- Expected cash reach
- First half of CY2028
- Company-stated cash reach
AI-generated analysis. How Rhea-AI works. Not financial advice.
SYDNEY, AUSTRALIA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces that it received an A
This follows approval from AusIndustry of Immutep’s application for an Advance overseas finding. Due to the Advance overseas finding, certain of Immutep’s overseas research and development activities were eligible for the R&D Tax Incentive, in addition to its eligible Australian activities.
Immutep also receives the French CIR tax incentive through its subsidiary Immutep S.A.S. in respect of expenditure incurred on eligible R&D activities conducted in the European Union.
In addition, Immutep is eligible for Germany’s R&D tax incentive program (Forschungszulage) in respect of qualifying internal R&D personnel costs of its German subsidiary, Immutep GmbH. Having received its first payment under this program in Q4 FY26, Immutep may receive further Forschungszulage payments in future years in respect of eligible R&D activities. Any such payments remain subject to the statutory application, assessment and review process, and their amount and timing are uncertain.
Immutep will apply the non-dilutive funding towards furthering its current R&D activities for its product candidates, efti and IMP761. The expected cash reach of the Company extends into the first half of CY2028.
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the intended use of the R&D tax incentive funding, the Company’s eligibility for and receipt of potential future R&D tax incentive payments, including under Germany’s Forschungszulage, the Company’s expected cash reach, anticipated clinical development, regulatory progress and the potential benefits of efti and IMP761. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.
Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, the cost and timing of the Company’s clinical programs, the availability of future funding, and the Company’s ability to advance its product candidates.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.
Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
US Investors/Media:
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com
This announcement was authorised for release by the CEO of Immutep Limited.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did Immutep receive under Australia’s R&D tax incentive program?
Immutep received A$856,669 for eligible research and development activities conducted in fiscal 2025. Approval of an Advance overseas finding allowed certain overseas activities to qualify alongside eligible Australian activities.
What will Immutep use the R&D rebate for?
Immutep will apply the non-dilutive funding to further research and development of efti and IMP761. The company expects its cash to last into the first half of CY2028.